CSBIO(SZ:300255)2022-12-06 11:21Group 1: Company Overview and Operations - Hebei Changshan Biochemical Pharmaceutical Co., Ltd. is focused on the development of hyaluronic acid and heparin series products [1] - The company is currently preparing to apply for production of injectable hyaluronic acid to the National Medical Products Administration [1] - The new hyaluronic acid workshop is designed with a production capacity of 20 tons, while the current capacity for food-grade and cosmetic-grade hyaluronic acid is approximately 1,000 kg [2] Group 2: Product Development and Clinical Trials - The company is collaborating with American Huangxinxiang to develop a new diabetes treatment, Aibennate, which is currently in Phase I clinical trials and progressing well [2] - The company plans to produce pharmaceutical-grade, food-grade, and cosmetic-grade products in the new hyaluronic acid workshop [2] Group 3: Market Strategy and Future Plans - The company is exploring acquisition opportunities in the pharmaceutical, medical services, and medical device sectors to support strategic growth [3] - The company aims to establish a blood dialysis center to meet the demand in Shijiazhuang and surrounding areas, addressing the current shortfall in public hospital capacity [3] - The independent dialysis center will focus on providing superior service and hygiene compared to public hospitals, leveraging collaboration with German D-Med for advanced dialysis standards [3]